SCHEMBL5845698

SCHEMBL5845698

Fc1ccc(F)c(-c2ccccn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.51
LMNA P02545 4/20 0.50
HTT P42858 3/20 0.50
TGFBR1 P36897 2/20 0.49
KDM4E B2RXH2 5/20 0.48
CCR1 P32246 3/20 0.48
CCR5 P51681 3/20 0.48
CCR8 P51685 3/20 0.48
METAP1 P53582 2/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
BLM P54132 1/20 0.48
HIF1A Q16665 1/20 0.48
DOHH Q9BU89 1/20 0.48
P4HTM Q9NXG6 1/20 0.48
METAP2 P50579 1/20 0.47
CBFB Q13951 1/20 0.47
CASP6 P55212 1/20 0.47
NPY5R Q15761 1/20 0.45
MAPK14 Q16539 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29353368 0.85 MEN1 (0.52) GRM5LMNAHTTTGFBR1KDM4E
SCHEMBL514547 0.85 MEN1 (0.52) GRM5LMNAHTTTGFBR1KDM4E
SCHEMBL29352118 0.85 MEN1 (0.52) GRM5LMNAHTTTGFBR1KDM4E
SCHEMBL2692720 0.83 GRM5 (0.54) GRM5LMNAHTTTGFBR1KDM4E
SCHEMBL4404741 0.83 GRM5 (0.51) GRM5LMNAHTTTGFBR1KDM4E
SCHEMBL1518061 0.83 MEN1 (0.51) GRM5LMNATGFBR1KDM4ECCR1
SCHEMBL31036229 0.83 MEN1 (0.51) GRM5LMNATGFBR1KDM4ECCR1
SCHEMBL31549509 0.83 MEN1 (0.51) GRM5LMNATGFBR1KDM4ECCR1
SCHEMBL30958581 0.83 MEN1 (0.51) GRM5LMNATGFBR1KDM4ECCR1
SCHEMBL7166636 0.83 MEN1 (0.51) GRM5LMNATGFBR1KDM4ECCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2025-04-24 US disclosed
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS XENON PHARMACEUTICALS INC. (CA) 2023-05-18 US disclosed
CN-107207514-B Fused heteroaryl compounds and their use as TRK inhibitors 康联制药有限公司 2020-01-24 CN disclosed
CN-103193568-B The selective hydrogenation reduction method of fluorine-containing arene derivatives 中国科学院上海有机化学研究所 2017-11-07 CN disclosed
CN-103193568-A Selective hydrogenation reduction method of fluorine-containing aromatic hydrocarbon derivative SHANGHAI INST ORGANIC CHEM 2013-07-10 CN disclosed
CN-1325503-C Luminous organic intermetallic compound and luminous element SANYO ELECTRIC CO (JP) 2007-07-11 CN disclosed
US-7067202-B2 Luminous efficiency and capable of emitting light of spectrum components of red or blue wavelength band; for use in organic electroluminescent device SANYO ELECTRIC CO., LTD. (JP) 2006-06-27 US disclosed
US-20030040627-A1 Luminescent organometallic compound and light emitting device SANYO ELECTRIC CO., LTD. (JP) 2003-02-27 US disclosed
CN-1397559-A Luminous organic intermetallic compound and luminous element SANYO ELECTRIC CO (JP) 2003-02-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129044-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1B, SCN1A, SCN2B GRM5 636/4885LMNA 287/4885HTT 4258/4885
US-20030040627-A1 Luminescent organometallic compound and light emitting device IK, CRY1, LBR GRM5 1398/4885LMNA 3413/4885HTT 3340/4885
US-20230150972-A1 PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1B, SCN1A, SCN2B GRM5 636/4885LMNA 287/4885HTT 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.